(Q51786016)

12 April 2018

title

Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). (English)

1 reference

12 April 2018

Elisabeth Steinhagen-Thiessen

1 reference

7

object named as

E Steinhagen-Thiessen

1 reference

12 April 2018

U Kassner

1

1 reference

12 April 2018

A Vogt

2

1 reference

12 April 2018

A Rosada

3

1 reference

12 April 2018

F Barz

4

1 reference

12 April 2018

E Giannakidou-Jordan

5

1 reference

12 April 2018

H K Berthold

6

1 reference

12 April 2018

publication date

1 December 2009

1 reference

12 April 2018

Atherosclerosis. Supplements

published in

1 reference

12 April 2018

volume

10

1 reference

12 April 2018

issue

5

1 reference

12 April 2018

page(s)

85-88

1 reference

12 April 2018

Lipoprotein(a) as a risk factor for coronary artery disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Lipoprotein(a): intrigues and insights

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

In Vivo Transfer of Lipoprotein(a) Into Human Atherosclerotic Carotid Arterial Intima

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Recommendations for the use of LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice: executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971818-5

7 January 2021

10.1016/S1567-5688(09)71818-5

Identifiers

DOI

1 reference

12 April 2018

PubMed ID

20129382

1 reference

12 April 2018